ArticleAmerican journal of respiratory and critical care medicine2009
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Article in American journal of respiratory and critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.The Cochrane database of systematic reviews · 2013Pooled it
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.The New England journal of medicine · 2019Trial
- Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.Antimicrobial agents and chemotherapy · 2010Trial
- One-Dose Efficacy of Long-Acting Sorfequiline in a Mouse Model of Tuberculosis Preventive Therapy.bioRxiv : the preprint server for biology · 2026Article
- Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.Antimicrobial agents and chemotherapy · 2024Article
- Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.Antimicrobial agents and chemotherapy · 2023Article
- Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy.bioRxiv : the preprint server for biology · 2023Article
- Mouse Models forPathogens (Basel, Switzerland) · 2022Review
- Review
- Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.American journal of respiratory and critical care medicine · 2022Article
- B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latentFrontiers in immunology · 2022Article
- Immunological aspects of host-pathogen crosstalk in the co-pathogenesis of diabetes and latent tuberculosis.Frontiers in cellular and infection microbiology · 2022Article
- Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.Antimicrobial agents and chemotherapy · 2021Article
- Reactivation of latent tuberculosis through modulation of resuscitation promoting factors by diabetes.Scientific reports · 2021Article
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.Current HIV/AIDS reports · 2020Review
- Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis.The Journal of clinical investigation · 2020Article
- Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.Antimicrobial agents and chemotherapy · 2019Article
- Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.Tuberculosis and respiratory diseases · 2018Review
- A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.EBioMedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
rationaleRegimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9 months long. A 2-month rifampin+pyrazinamide regimen is no longer recommended. Shorter regimens are highly desirable. Because substituting rifapentine for rifampin in the standard regimen for active tuberculosis halves the treatment duration needed to prevent relapse in mice, we hypothesized daily rifapentine-based regimens could shorten LTBI treatment to 2 months or less.
objectivesTo improve an existing model of LTBI chemotherapy and evaluate the efficacy of daily rifapentine-based regimens.
methodsMice were immunized with a more immunogenic recombinant Bacille Calmette-Guérin strain (rBCG30) and received very low-dose aerosol infection with Mycobacterium tuberculosis to establish a stable lung bacterial burden below 10(4) CFU without drug treatment. Mice received a control (isoniazid alone, rifampin alone, rifampin+isoniazid, rifampin+pyrazinamide) or test (rifapentine alone, rifapentine+isoniazid, rifapentine+pyrazinamide, rifapentine+isoniazid+pyrazinamide) regimen for 8 weeks. Rifamycin doses were 10 mg/kg/d, analogous to the same human doses. Outcomes were biweekly lung CFU counts and relapse after 4 to 8 weeks of treatment. MEASUREMENTS AND MAIN
resultsM. tuberculosis CFU counts remained stable around 3.65 log(10) in immunized, untreated mice. Isoniazid or rifampin left all or most mice culture-positive at week 8. Rifampin+isoniazid cured 0 and 53% of mice and rifampin+pyrazinamide cured 47 and 100% of mice in 4 and 8 weeks, respectively. Rifapentine-based regimens were more active than rifampin+isoniazid and indistinguishable from rifampin+pyrazinamide.
conclusionsIn this improved murine model of LTBI chemotherapy with very low lung burden, existing regimens were well represented. Daily rifapentine-based regimens were at least as active as rifampin+pyrazinamide, suggesting they could effectively treat LTBI in 6 to 8 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.